Amicomed Inc.
Location: 1275 Mission Street, San Francisco, California, United States United States
Founded in: 2015
Stage: Pre-launch
Number of employees: 6-15
Funding history:
- Date: 07/2017, Seed: undisclosed amount
Investors: Francesco Turrini, claudio torcellan, Nicola Brandolese, Harald Rösch, Marco Bragadin, Andrea Federico, DOMENICO CIANFLONE
Investment Firms: Launchpad Digital Health
Short URL:
Awards and mentions
Poster titles "Prevalence of Optimal Blood Pressure Values in Digital-Savvy Hypertensives" peer-reviewed and selected to present at the American Society of Hypertension (New York 2016)
An Effective mHealth Service to Reduce Blood Pressure Without Adding Medications Through Personalized Automated Lifestyle Interventions

We are excited to back the entrepreneurs leading in this space. Amicomed: mastering your blood pressure with an innovative digital platform. Proven to effectively treat hypertension in Europe now debuting in the U.S. and backed by leading Cardiologists. CEO – Giangiacomo Rocco di Torrepadula


Amicomed Inc.

Master your blood pressure
San Francisco, California, United States United States
  • About
  • >
  • Activities
  • >
  • News
Company description

Amicomed is the first fully digital platform for Blood Pressure (BP) management combining innovative remote monitoring and lifestyle intervention.

Amicomed leverages proprietary algorithms to provide tangible outcomes through innovative management of chronic diseases. The platform supports physicians with remote monitoring tools enhanced by vitals pattern analysis, and actionable, consumer-grade designed, personalized lifestyle intervention for their patients. 
The platform has been designed to manage all main cardiovascular conditions; BP is the first.

Amicomed's first results in Europe have been striking: 70% adherence with a mean BP reduction (sys) of 5mmHg (up to 20mmHg), peer reviewed and presented to major international congresses (ACC, ASH, ESH, ISH)

The company is currently being accelerated in by Launchpad Digital Health in San Francisco.


  • Giangiacomo Rocco di Torrepadula
    Giangiacomo Rocco di Torrepadula | Founder
    Serial entrepreneur passionate for startups. MBA (Bocconi), McKinsey. In 2000 cofounded Pharmaidea (at his exit fully profitable, €150 mln rev, and 150 employees). Now cofounder and CEO of Amicomed, digital platform for blood pressure management
    Lecturer in Cardiovascular Medicine and Director Cardiovascular Prevention and Rehabilitation Unit at San Raffaele Hospital Founding Member International Heart Health Society Experience in Health IT, founding member Health On The Net (Geneva)
  • Andrea Mason
    Andrea Mason | Team member
    In1996 I founded of Telbios (today serving tens of thousands of chronic patients), then responsible for the E2E service design in the largest European initiative of Population management. Mentor at Stanford at the class 'Biodesign for mobile health.
    PAUL PETRONELLI | Team member
    20+ years experience in product development and security and cross-functional industry expertise: government contractors and large software vendors (Microsoft) to start-ups. Strong experience in healthcare, high tech and communications.
Business model

We deliver outcomes. We will address B2B customers that can receive tangible clinical and economic benefits from our outcomes. We target care-providers linked to quality metrics (e.g. ACOs, BPCI), impacting positively their quality scores, avoiding losses/gaining benefits (hence willing to pay for Amicomed) as well as payers, increasing potential users and improving the service.

Competitive advantage

In the BP arena, no one provides all the benefits we deliver. Digital therapies (e.g. Omada) aren't focused on BP or fully automated. General wellness programs (e.g. WellTok) don't provide data analysis and aren't focused on BP. Medication reminders (e.g. Medisafe) or BP device companies (e.g. Omron) have BP focus but don't provide data analysis or lifestyle intervention. BP apps are only journals with no data analysis/lifestyle intervention.

We feel our main competitive advantages are:

-So far no one offers our entire streamline of features (remote monitoring and lifestyle intervention, fully automated and focused on BP)

-Proven clinical outcomes: mean BP reduction of 5mmHg (up to 20) and 70% adherence presented at major congresses

-2 proprietary algorithms (over 3years R&D to develop/implement)

-International scientific recognition

-Management Team: unique mix with decades of experience in health and clinical innovation

Furthermore, please note that - due to complementary nature of the services offered - each of the above mentioned competitors could also be a potential partner (indeed we are already partnered with BP device companies like iHealth as well as having other conversations with complementary players).


Launchpad Digital Health - Unconfirmed
Next Generation Digital Health Accelerator   Open for New Applications for Next Group of Companies First Group of Companies Funded & Achieving Liftoff Unique Environment: Located in San Francisco - SOMA, co-located with Founders Al...
Investor Deafult Image
Christian Miccoli - Unconfirmed
Investor Deafult Image
Giovanni Viani - Unconfirmed
Investor Deafult Image
Roberto Lancellotti - Unconfirmed
Nicola Brandolese
Manager across corporations: Boston Consulting Group, Sapient, Sky, Luxottica Group
Investor Deafult Image
Vincenzo Tortrici - Unconfirmed
Lecturer in Cardiovascular Medicine and Director Cardiovascular Prevention and Rehabilitation Unit at San Raffaele Hospital Founding Member International Heart Health Society Experience in Health IT, founding member Health On The Net (Geneva)